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ATG5 is induced by DNA-damaging agents
and promotes mitotic catastrophe independent
of autophagy
Dipak Maskey1, Shida Youseﬁ1, Ine`s Schmid1, Inti Zlobec2, Aurel Perren2, Robert Friis1 & Hans-Uwe Simon1
Anticancer drug therapy activates both molecular cell death and autophagy pathways. Here
we show that even sublethal concentrations of DNA-damaging drugs, such as etoposide and
cisplatin, induce the expression of autophagy-related protein 5 (ATG5), which is both
necessary and sufﬁcient for the subsequent induction of mitotic catastrophe. We demon-
strate that ATG5 translocates to the nucleus, where it physically interacts with survivin in
response to DNA-damaging agents both in vitro and in carcinoma tissues obtained from
patients who had undergone radiotherapy and/or chemotherapy. As a consequence,
elements of the chromosomal passenger complex are displaced during mitosis, resulting in
chromosome misalignment and segregation defects. Pharmacological inhibition of autophagy
does not prevent ATG5-dependent mitotic catastrophe, but shifts the balance to an early
caspase-dependent cell death. Our data suggest a dual role for ATG5 in response to drug-
induced DNA damage, where it acts in two signalling pathways in two distinct cellular
compartments, the cytosol and the nucleus.
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acroautophagy (herein autophagy) is a process that
occurs in response to stress in yeast, plants and
mammalian cells by which a portion of the cytosol is
sequestered in characteristic double- or multi-membrane vesicles
to form autophagosomes. The molecular mechanisms of
autophagosome formation are conserved in evolution and depend
upon several autophagy-related proteins (ATGs). One of these is
the ATG5, which conjugates with ATG12 to generate an E3
ubiquitin ligase-like enzyme required for autophagy1. Mice
deﬁcient in the atg5 gene die on the ﬁrst day after birth2. Once
formed, autophagosomes merge with lysosomes to form
autolysosomes whose contents are degraded by lysosomal
hydrolases1.
Both autophagic and apoptotic pathways are activated during
anticancer drug treatment3. As autophagy is a survival
mechanism, one can speculate that autophagy induced by
anticancer drugs might contribute to resistance to treatment in
cancer patients4. The goal of our study was to investigate the role
of ATG5 in the responses of cells to different DNA-damaging or
antimitotic drugs at sublethal concentrations, which elicit little
cell death. This allows dissecting in detail the biochemical
responses to such an insult within the ﬁrst days after treatment.
We show that ATG5 is upregulated in cancer cells following
treatment with DNA-damaging drugs, both under in vitro and
in vivo conditions. Moreover, ATG5 also translocates to the
nucleus where it physically associates with survivin. Mitotic
catastrophe ensues, which, if the cytoplasmic autophagic pathway
is concurrently blocked pharmacologically, proceeds rapidly to
caspase-dependent cell death.
Results
DNA-damaging drugs induce ATG5 and mitotic catastrophe.
To investigate the role of autophagy in anticancer drug treat-
ment, we decided to study the effects of different drugs at sub-
lethal concentrations as determined for six antimitotic and
DNA-damaging drugs in multiple experiments (the procedure is
illustrated in Supplementary Fig. S1). Jurkat T cells were exam-
ined over the ﬁrst 4 days after treatment with these six different
drugs, each at the deﬁned sublethal concentration, and classiﬁed
morphologically as normal, apoptotic or abnormal. The latter
case comprised enlarged cells with enlarged, irregular nuclei,
cells exhibiting abnormal, multipolar mitoses and multinucleated
cells (Fig. 1a). The apoptotic fraction was relatively modest at
2–6% (Fig. 1a). Cells treated with etoposide, cisplatin, taxol or
nocodazole, however, showed 40–80% abnormal morphology,
exhibiting enlarged, irregular nuclei, multipolar mitoses, or
multiple nuclei, characteristic of mitotic catastrophe5. Mitotic
catastrophe is deﬁned in international consensus as an
oncosuppressive phenomenon occurring during or after
defective mitosis leading to death or senescence.6 On the other
hand, inefﬁcient mitotic catastrophe with mitotic slippage can
lead to the emergence of genetically unstable, tumorigenic,
aneuploid cell population5–7.
As, under the conditions used, only little cell death occurred up
to 4 days after initiation of treatment (Supplementary Fig. S1), we
investigated the molecular pathway of autophagy following
exposure of Jurkat T cells to etoposide, cisplatin, taxol or
nocodazole. Whereas etoposide and cisplatin induced autophagy
as assessed with a biochemical analysis in which we observed the
conversion from cytosolic LC3-I to membrane-bound LC3-II,
these changes were largely absent in cells treated with taxol or
nocodazole (Fig. 1b). A chloroquine control indicated that the
accumulation of LC3-II after etoposide or cisplatin treatment was
indeed a result of increased autophagic ﬂux8. We then analysed
ATG5, Beclin 1 (ATG6) and ATG12 expression levels. Autophagy
induction was accompanied by increased levels of ATG5, which
was largely seen as the ATG5–ATG12 conjugate (59 kDa), but
also, although less, as the monomer (32 kDa) (Fig. 1b). The
presence of ATG12 in the conjugate was conﬁrmed with anti-
ATG12 antibody (Fig. 1b). In contrast to ATG5, Beclin 1 was not
induced by etoposide or cisplatin (Fig. 1b), and neither ATG5 nor
Beclin 1 was signiﬁcantly increased following taxol or nocodazole
treatment (Fig. 1b).
We subsequently investigated other cell types, observing a
similar induction of autophagy associated with increases in ATG5
expression following etoposide or cisplatin treatment
(Supplementary Fig. S2a). In these experiments, we conﬁrmed
the increased autophagic ﬂux by demonstrating diminished levels
of p62, a marker protein that functions as a link between LC3 and
the ubiquitinated substrates8. Autophagosome formation could
also be directly visualized when HeLa cells expressing ﬂuorescent
LC3 (LC3–GFP) were examined following etoposide or cisplatin
exposure (Supplementary Fig. S2b). Moreover, treated cells
showed characteristic mitotic catastrophe with enlarged,
irregular nuclei and/or multiple nuclei after Giemsa/May–
Gru¨nwald staining (Supplementary Fig. S2c).
Mitoses of HeLa cells expressing histone 2b (H2B–mCherry)
and a-tubulin (EGFP–a-tubulin)9 were photographed with
ﬂuorescence live microscopy after treatment with DNA-
damaging drugs. Unlike the normal metaphase plate and
bipolar spindles seen with untreated cells, drug-treated cells
revealed the formation of multipolar spindles as well as
misaligned and missegregated chromosomes characteristic of
mitotic catastrophe10 (Fig. 2a). Quantitative analysis of this cell
population showed that the development of abnormal nuclei is
time-dependent and occurs in the majority of both etoposide-
and cisplatin-treated cells (Fig. 2b). Taken together, our ﬁndings
indicate that both etoposide and cisplatin induce ATG5
expression, autophagy and mitotic catastrophe in multiple cell
lines. In contrast, taxol and nocodazole treatment resulted in
mitotic catastrophe, but without producing elevated ATG5 levels
or increased autophagic activity.
Critical role of ATG5 for mitotic catastrophe. The elevation of
ATG5 levels after etoposide and cisplatin treatment could be
inhibited using two different short hairpin RNAs (shRNAs;
Fig. 3a). Blocking ATG5 expression prevented both the induction
of autophagy, as assessed by LC3 immunoblotting (Fig. 3a), and
the appearance of cells with abnormal nuclei (Fig. 3b). A control
shRNA had no effect in these assays (Fig. 3a,b). These data
suggested that increased levels of ATG5 are necessary for mitotic
catastrophe following exposure to DNA-damaging drugs.
To test whether ATG5 is sufﬁcient to induce mitotic
catastrophe, a human ATG5 construct was introduced into
Jurkat T cells using a lentiviral gene expression system. As
controls, Beclin 1 overexpression with a parallel construct or a
drug treatment with rapamycin, both known to induce
autophagy11,12, as well as etoposide treatment, were employed.
Ectopic ATG5 overexpression, such as etoposide treatment, but
neither Beclin 1 overexpression nor rapamycin treatment,
resulted in multinucleated cells and mitotic catastrophe (Fig. 3c,
micrographs). Quantitative analysis revealed that more than 50%
of the cells after lentiviral ATG5 gene transfer demonstrated
abnormal nuclei (Fig. 3c, right panel). The induction of
autophagy by enforced Beclin 1 expression or rapamycin
treatment was controlled by LC3 immunoblotting experiments
(Fig. 3d). To answer the question whether ATG5 conjugation to
ATG12 is required for induction of mitotic catastrophe, as is the
case for inducing autophagy13, we also included cultures
transduced with the mutant ATG5 (ATG5-K130R) (Fig. 3c),
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Figure 2 | DNA-damaging drugs induce mitotic catastrophe. (a) Time-lapse microscopy. HeLa H2B–mCherry–a-tubulin–EGFP cells were cultured in the
presence and absence of etoposide and cisplatin, respectively. Treated cells frequently developed multiple nuclei, including micronuclei (upper panel), and
demonstrated evidence of multipolar spindles and misaligned chromosomes (lower panel). Cells were also much larger than untreated cells (see also
Supplementary Fig. S3). Scale bar, 10mm. (b) Statistical analysis of the data shown above. At least 100 cells were counted for each drug exposure time
according to the classiﬁcation used in Fig. 1. Values are means±s.d. (n¼ 3).
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Figure 1 | Sublethal concentrations of anticancer drugs induce multinucleated cells and autophagy. (a) Morphological analysis. Jurkat T cells were
cultured in the presence and absence of the indicated anticancer drugs for 48 h. Drug-treated cells were classiﬁed as normal, apoptotic or abnormal, with
enlarged and irregular nuclei, with multipolar mitoses or multinucleated. Cultures treated with etoposide (0.25 mM), cisplatin (3 mM), taxol (4 nM)
and nocodazole (10 nM) exhibited high levels of cells with abnormal nuclei. None of the treated populations showed a signiﬁcant fraction of apoptosis (see
also Supplementary Fig. S1). Values are means±s.d. for three independent experiments. Right: representative examples of these morphological categories
are shown. Scale bar, 10mM. Similar abnormalities were also seen after treating NB4 and MDA-MA-231 cells with etoposide or cisplatin (Supplementary
Fig. S2). (b) Immunoblotting. Jurkat T cells were treated as indicated and ATG5 (monomeric and ATG12-conjugated), ATG12 (conjugated with ATG5),
LC3 (18 and 16 kDa), Beclin 1 and GAPDH detected. Chloroquine (CQ) was employed to block lysosomal proteases. Each immunoblot is representative of at
least three independent experiments. The same assays were performed using NB4 and MDA-MA-231 cells (Supplementary Fig. S2). Moreover, as a marker
for autophagy onset, increased LC3-II formation following etoposide or cisplatin treatment was also documented using ﬂuorescence microscopy
(Supplementary Fig. S2). Full-length immunoblots are provided in Supplementary Fig. S8.
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which is unable to conjugate with ATG12 (ref. 14). Interestingly,
overexpression of ATG5-K130R also triggered the appearance
of multinucleated cells (Fig. 3c), indicating that ATG5 is able
to induce mitotic catastrophe independent of its conjugation with
ATG12. Successful gene transfer was controlled by
immunoblotting (Fig. 3d).
Enforced ATG5 expression was employed in HeLa H2B–
mCherry–a-tubulin–EGFP cells, which were then analysed by
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Figure 3 | ATG5 is necessary and sufﬁcient for anticancer drug-induced mitotic catastrophe. (a) Immunoblotting. Jurkat T cells were cultured as
indicated for 48 h. Only under conditions of ATG5 induction was evidence of increased autophagic activity obtained. Monomeric ATG5 (shown
under the dotted line) was detected after a longer exposure time compared with the ATG5 conjugated with ATG12. Results are representative of three
independent experiments. (b) Morphological analysis. Jurkat T cells were cultured as in a. Values are means±s.d. of three independent experiments.
(c) Morphological analysis. Jurkat T cells were treated with the indicated drugs or transduced with lentivirus ATG5, ATG5-K130R, Beclin 1 or control
constructs for 48 h. Enlarged and multinucleated cells were seen as a consequence of ATG5 or ATG5-K130R lentiviral gene transfer or of etoposide
treatment. Increased Beclin 1 levels or rapamycin treatment had no such effect. Representative examples of morphology are shown. Scale bar, 10mm. Right:
statistical analysis of the data. At least 100 cells were counted for each condition. Values are means±s.d. (n¼ 3). (d) Immunoblotting. Enforced expression
of ATG5, Beclin 1, or ATG5-K130R following lentiviral gene transfer. (e) Time-lapse microscopy. HeLa H2B–mCherry–a-tubulin–EGFP cells were transduced
by lentiviral gene transfer as indicated. Only ATG5-overexpressing cells demonstrated evidence for mitotic catastrophe (see also Supplementary Movies).
As with the GFP control, the Beclin 1 construct also included GFP, hence the intensity in green was very high. Scale bar, 10mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3130
4 NATURE COMMUNICATIONS | 4:2130 | DOI: 10.1038/ncomms3130 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
ﬂuorescence live microscopy to show the morphology of the
mitosis induced. Whereas uninfected cells or cells overexpressing
green ﬂuorescent protein (GFP) or Beclin 1 underwent mainly
normal mitosis, cells overexpressing ATG5 exhibited unequally
segregated chromosomes resulting in progeny with multiple
nuclei (Fig. 3e and Supplementary Movies 1–4). Moreover, the
average time period between nuclear envelope breakdown and
anaphase was longer in ATG5-overexpressing cells
(Supplementary Movies 1–4; control, 41min; ATG5, 83min;
GFP, 42min; Beclin 1, 43min). The chromosomal abnormalities
were visible already in the prometaphase and developed into
nuclei that were irregular, shrunken and fragmented (Fig. 3e and
Supplementary Movie 2). Quantitative analysis revealed that the
majority of abnormalities were seen in the anaphase, reaching
B50% of all mitotic cells observed in cytospin samples taken at
48 h after ATG5 transduction. An abnormal metaphase was seen
in about 8% of cells undergoing mitosis at this time point.
Moreover, ATG5-overexpressing cells exhibited a larger size (see
also Supplementary Fig. S3) with rounded morphology (Fig. 3e
and Supplementary Movie 2).
We next investigated whether enforced ATG5 expression
would alter cell cycle regulation. Jurkat T cells were transduced
with ATG5 or GFP, after which cell cycle analysis was performed
daily using propidium iodide (PI) cytometry. Although GFP
overexpression had only marginal effects, enforced expression of
ATG5 resulted in an increased fraction of cells in the G2 or M
phases of cell cycle, a fraction increasing with time of exposure
(Fig. 4a). As a positive control, we used etoposide, which also
induced such arrest (Fig. 4a). Interestingly, etoposide-mediated
effects on the cell cycle appeared to depend on increased
expression of ATG5, as shRNA ATG5 prevented accumulation of
cells in G2 or M phases (Fig. 4b). To limit the number of different
conditions to be analysed per experiment, in all subsequent
assays, we have used etoposide as a model drug for inducing DNA
damage.
Protein levels of cell cycle regulators were studied to better
understand the G2/M block. Unsurprisingly, cyclin B1 was
stabilized by both etoposide treatment and ectopic ATG5
expression (Fig. 4c, upper panel) in agreement with the increasing
number of cells showing arrest at G2 or M phases15. Cyclin-
dependent kinase 1 (cdk1) expression was somewhat increased
and was found to be strongly phosphorylated in tyrosine 15
(Fig. 4c, upper panel). In contrast, in GFP vector control or
rapamycin-treated cells, tyrosine 15 phosphorylation of cdk1 was
reduced (Fig. 4c, upper panel). Both enforced expression of ATG5
and etoposide treatment led to phosphorylation of the Chk2 in
threonine 68, thus activating the Chk2 signalling pathway
(Fig. 4c, lower panel). Moreover, these data clearly indicate that
at least a cell subpopulation already exhibits an arrest in the G2
phase under these conditions.
Moreover, lentiviral ATG5 gene transfer led to immediate
conversion of cytosolic LC3-I into the autophagosome-speciﬁc
LC3-II form, as did etoposide or rapamycin treatment (Fig. 4c,
upper panel). The degradation of p62 protein conﬁrmed high
autophagic activity in ATG5-overexpressing, as well as in
etoposide- or rapamycin-treated, cells (Fig. 4c, lower panel).
We also analysed phosphorylated histone H2AX (phospho-
H2AX) expression, an early DNA damage response marker16, by
ﬂow cytometry, confocal microscopy and immunoblotting. In
contrast to untreated and ATG5- or GFP-overexpressing cells,
this measure of DNA damage was only signiﬁcantly elevated in
cells treated with sublethal concentrations of etoposide (Fig. 5a–c).
Moreover, we detected phospho-ataxia telangiectasia-mutated
kinase (ATM) (Ser1981) and phospho-ataxia telangiectasia and
Rad3-related kinase (ATR) (Ser428), two additional markers of
the DNA damage response, and observed again no increased
phosphorylation as a consequence of ATG5 gene transfer
(Fig. 5c).
ATG5-mediated mitotic catastrophe is autophagy-independent.
As the ATG5-K130R mutant, which is itself unable to conjugate
with ATG12, still induced mitotic catastrophe (Fig. 3c), we
investigated the relationship between autophagy, G2 and M phase
arrest, and mitotic catastrophe in more detail. Autophagy was
induced both by starvation and by ectopic expression of Beclin 1.
Although starvation indeed rapidly increased autophagic activity
as assessed by accumulation of LC3-II and degradation of p62, no
G2- and M-phase arrest was observed (Supplementary Fig. S4a).
In fact, increased numbers of cells were observed in G1 arrest
following starvation. Furthermore, cyclin B1 expression declined
(Supplementary Fig. S4a,b). Similarly, overexpression of Beclin 1
was associated with induction of autophagy and reduced cyclin B1
levels, but had no effect on the cell cycle (Supplementary Fig.
S4a,b). Moreover, neither starvation nor Beclin 1 transduction
induced the morphological features of mitotic catastrophe
(Supplementary Fig. S4c).
Although this experiment conﬁrmed that autophagy is not
necessarily linked to G2- and M-phase arrest and mitotic
catastrophe, an ATG5-mediated, increased autophagic activity
might still be causally related to cell cycle arrest and mitotic
catastrophe. Pharmacological inhibition of autophagy using
3-methyladenine (3-MA) (refs 17,18) blocked ATG5-mediated
LC3-II accumulation and p62 degradation (Fig. 6a),
demonstrating the functionality of the inhibitor in this system.
However, 3-MA neither prevented ATG5-induced G2- and
M-phase arrest (Fig. 6b) nor the nuclear abnormalities
described above (Fig. 6c). 3-MA alone had no effect either on
cell cycle or the fraction of cells with nuclear abnormalities.
ATG5- or etoposide-driven mitotic catastrophe was associated
with little cell death; however, in combination with 3-MA
treatment we observed dramatic cell death, which could be
blocked by pharmacological inactivation of caspases using 20mM
zVAD (z-Val-Ala-Asp) treatment (Fig. 6d). Thus, ATG5 induces
G2- and M-phase arrest and mitotic catastrophe independently of
its capacity to enhance autophagic activity. Autophagy, on the
other hand, is required for cell survival under these conditions.
ATG5 translocates to the nucleus. We hypothesized that if
increased ATG5 expression after etoposide or cisplatin treatment
is indeed functionally linked to G2- and M-phase arrest and
mitotic catastrophe, it may require translocation to the nucleus to
fulﬁll this role. Indeed, as could be demonstrated with cell frac-
tionation experiments, etoposide treatment caused increased,
especially monomeric ATG5 levels in both cytoplasm and nucleus
of Jurkat T cells (Fig. 7a). The purity of cytoplasmic and nuclear
fractions was controlled here using antibodies against caspase-3
and lamin B, which served as markers for the cytoplasmic and
nuclear compartments, respectively (Fig. 7a).
We detected in ATG5 a conserved sequence homologous to the
leucine-rich nuclear export signal (NES) of Beclin 1 (ref. 19;
Fig. 7b). Exposure of etoposide-treated or ATG5-overexpressing
cells to leptomycin B, an inhibitor of the exportin-1 (CRM1)-
dependent nuclear export20, caused accumulation of both Beclin
1 and ATG5 in the nucleus (Fig. 7c). We prepared a mutated
ATG5 construct in which the human ATG5 sequence was
modiﬁed, replacing three of the four most conserved leucines
with alanines (Fig. 7b). Surprisingly, expression of this NES-
mutated form of ATG5 (ATG5-DNES) failed to accumulate in the
nucleus and was detectable in the cytoplasm only (Fig. 7d), where
it was still able to induce autophagy as assessed by LC3-II
accumulation and p62 degradation (Fig. 7e). In contrast to ATG5,
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Figure 4 | Enforced expression of ATG5 induces G2- or M-phase arrest. (a) Cell cycle analysis. After lentivirus gene transfer, Jurkat Tcells overexpressing
ATG5 or GFP were followed for the indicated times and analysed for DNA content by ﬂow cytometry. Untransduced cells were left untreated or treated
with etoposide for comparison. Values are means±s.d. (n¼ 3). Right: representative ﬂow cytometry diagrams for the 48 h time point. (b) Cell cycle
analysis. Jurkat cells were cultured as indicated for 48 h. Only under conditions of ATG5 induction, we observed an accumulation of cells in G2- or M-phase
arrest. Results are representative of three independent experiments. (c) Immunoblotting. Jurkat T cells overexpressing ATG5 or GFP were cultured
for the indicated times after transduction and analysed. As controls, cells were treated with etoposide or rapamycin. Although rapamycin, similar to
etoposide, induced autophagy, no increase in ATG5 expression and no cell cycle arrest were observed. ATG5 overexpression and etoposide treatment
resulted in a similar expression pattern for all proteins investigated. Each immunoblot is representative of at least three independent experiments.
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however, enforced expression of this ATG5-DNES caused neither
G2 and M phase arrest (Fig. 7f) nor mitotic catastrophe (Fig. 7g).
These ﬁndings suggest that the putative NES must overlap a
cryptic, but functional nuclear localization motif (NLS) required
for the transport of ATG5 from the cytoplasm to the nucleus.
ATG5 and survivin physically interact in the nucleus. We
hypothesized that increased nuclear expression of ATG5 might
disturb chromosome segregation by interacting with other pro-
teins, such as elements of the chromosomal passenger complex
contributing to chromatin-associated spindle formation21.
Interestingly, we could show that following enforced ATG5
expression, survivin was upregulated, speciﬁcally in the mRNA
levels of the so-called wild-type survivin22, whereas the
expression levels of other survivin isoforms did not change
(Supplementary Fig. S5).
To test the possibility that survivin interacts physically with
ATG5 following etoposide treatment or ectopic overexpression, we
performed coimmunoprecipitation assays using antibodies for both
ATG5 and survivin. The presence of survivin in the ATG5 immuno-
precipitate and, reciprocally, ATG5 in the survivin immuno-
precipitate, was unambiguous both with ATG5 overexpression and
etoposide treatment of Jurkat T cells (Fig. 8a). In a further
coimmunoprecipitation experiment, we demonstrated that ATG5-
DNES failed to interact with survivin (Fig. 8b), suggesting that the
interaction takes place in the nucleus, where ATG5-DNES is absent,
or, alternatively, that an interaction with survivin depends on the
mutated leucine-rich sequence modiﬁed in ATG5-DNES. In contrast
to ATG5-DNES, the ATG5-K130R mutant, which is able to mediate
mitotic catastrophe (Fig. 3c), interacted with survivin (Fig. 8c).
Moreover, calpain-mediated 24-kDa truncated ATG5 (ref. 23) was
unable to interact with survivin (Fig. 8d), suggesting that the amino-
terminal part of ATG5 is most likely not responsible for the
interaction with survivin.
Evidence for molecular interactions between ATG5 and
survivin was also obtained when cells were analysed by
immunoﬂuorescence staining and confocal microscopy, as
performed with the large, ﬂat cells of the MDA-MA-231 line.
In untreated interphase cells, endogenous ATG5 and survivin
c
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are means±s.d. (c) Jurkat T cells were treated as in a and analysed by immunoblotting. Besides phospho-H2AX (Ser139), we also detected phospho-ATM
(Ser1981) and phospho- ATR (Ser428), two additional markers of DNA damage response. Intensity of the protein bands were quantiﬁed with a Licor/Odyssey
scanner and software (shown beneath each immunoblot). The fold change in phosphorylation levels compared with no treatment (untreated) are presented. The
data in all panels are representative of at least three independent experiments. Full-length immunoblots are provided in Supplementary Fig. S9.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3130 ARTICLE
NATURE COMMUNICATIONS | 4:2130 | DOI: 10.1038/ncomms3130 | www.nature.com/naturecommunications 7
& 2013 Macmillan Publishers Limited. All rights reserved.
were expressed in the cytosol, but no signiﬁcant colocalization
was observed (Fig. 8e). Upon etoposide treatment or ectopic
ATG5 overexpression, signiﬁcant levels of ATG5 were observed
in the nucleus where colocalization with survivin could be
detected (Fig. 8e). In contrast, in ATG5-DNES-overexpressing
cells ATG5 expression was seen in the cytosol only, again with
little evidence of colocalization with survivin (Fig. 8e).
Aurora B is a protein that is known to interact with survivin in
forming the chromosomal passenger complex24. We observed
reduced levels of interaction between Aurora B and survivin in
both Aurora B-speciﬁc and survivin-speciﬁc immunoprecipitates
of cells overexpressing ATG5 (Fig. 8f). This ﬁnding is consistent
with the hypothesis that ATG5 competes with Aurora B for
available survivin, with the consequence, presumably, that
formation of the chromosomal passenger complex is disturbed.
The ATG5-K130R mutant had the same effect (Fig. 8f). Within
the immunoprecipitate speciﬁc for Aurora B, ATG5 was not
detectable (Fig. 8f). Moreover, the amount of borealin, another
chromosomal passenger complex protein25, was unaffected by
increased levels of nuclear ATG5 or ATG5-K130R (Fig. 8f). We
also searched for HSP90 in this protein complex, as an earlier
report suggested that survivin interacts with HSP90 to prevent
proteasomal degradation of survivin26. We obtained, however, no
evidence that HSP90 is physically linked to either Aurora B or
survivin (Fig. 8f).
We next analysed the recruitment of chromosomal passenger
complex proteins to centromeres during mitosis27,28. Using
indirect immunoﬂuorescence experiments, we observed that
c
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during abnormal mitosis of etoposide-treated or ATG5-
transduced cells, Aurora B appeared to be mislocated and was
found much less at centromeres in prometaphase as compared
with normal mitoses of untreated cells (Fig. 8g). ATG5-DNES-
overexpressing cells demonstrated normal Aurora B
recruitment to centromeres, suggesting that only the presence
of newly recruited nuclear ATG5 is able to bring about the
displacement of this chromosomal passenger protein.
In contrast to Aurora B, survivin did not appear to be reduced
or displaced from the centromeres at prometaphase in cells with
increased levels of nuclear ATG5 (Fig. 8g). However, in contrast
to normal mitoses in which survivin was located at the central
spindle during anaphase, survivin was displaced and remained
at the centromeres in the majority of mitotic etoposide-treated
or ATG5-transduced cells (Fig. 8g). Similarly, Aurora B was
also mislocated during anaphase in cells with elevated nuclear
ATG5 levels and was not found at the central spindle as seen
during normal mitoses in untreated or ATG5-DNES transduced
cells (Fig. 8g). These abnormalities, seen in both prometaphase
and anaphase were associated with severe chromosome alignment
and segregation defects (Fig. 8g), supporting the assumption
that the nuclear interaction between ATG5 and survivin is
followed by a disturbance of the chromosomal passenger complex
during mitosis.
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We have also observed nuclear ATG5 expression in carcinoma
tissues of the lung and esophagus after patients had received
DNA-damaging radio- and/or chemotherapy (Fig. 8h). In
contrast, in specimens obtained from patients having received
no prior radio- and/or chemotherapy, ATG5 was detected almost
entirely in the cytosol (Fig. 8h). Moreover, cancer cells expressed
survivin at high levels, which strongly colocalized with ATG5 after
anticancer treatment (Fig. 8h). We also obtained evidence for
reduced survivin–Aurora B molecular interactions in specimens of
cancer cells having received treatment (Supplementary Fig. S6).
These data clearly suggest that the ﬁndings reported in this paper
are of in vivo relevance.
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Discussion
In this study we have investigated molecular events involved in
mitotic catastrophe caused by DNA-damaging agents and report
the following new ﬁndings: ﬁrst, these agents upregulate ATG5
expression, which is both necessary and sufﬁcient to induce
mitotic catastrophe in an autophagy-independent manner.
Second, ATG5 is not only a cytosolic protein, it is also expressed
in the nucleus. Nuclear ATG5 accumulates following DNA
damage, a ﬁnding, observed under both in vitro and in vivo
conditions. Interestingly, a NES-like motif apparently overlaps
with cryptic sequences acting as a NLS, thus supporting nuclear
translocation. Third, ATG5 associates with survivin in the
nucleus following drug-induced DNA damage under both
in vitro and in vivo conditions. Fourth, ATG5 seems likely to
inﬂuence the composition of the chromosomal passenger
complex by reducing the interaction between survivin and
Aurora B. Fifth, mitotic catastrophe induced by nuclear ATG5
is not associated with induction of cell death, as long as an
autophagic response is maintained. Following a pharmacological
block of autophagy, however, the cells promptly undergo caspase-
dependent cell death.
In agreement with earlier reports3,5, this study supports the
idea that anticancer drugs cause apoptosis, autophagy and mitotic
catastrophe. Whereas apoptosis of cancer cells is a clear
therapeutic goal, the induction of both autophagy and mitotic
catastrophe may cause problems. Autophagy can, at least under
certain conditions, exhibit tumour-promoting effects4. Similarly,
mitotic catastrophe does not always lead to cell death and has
been described as a cancer cell survival mechanism29,30.
Moreover, mitotic catastrophe in the absence of subsequent
cell death favours potentially oncogenic polyploidization6. It
should be noted that under the conditions used in this study,
mitotic catastrophe, whether induced by anticancer drugs or by
ectopic ATG5 overexpression, was generally not followed by cell
death in the time frame investigated (up to 96 h for the in vitro
studies). Interestingly, ATG5 appeared to have an important dual
role in this scenario. Although cytosolic ATG5 contributed to
increased autophagic activity, nuclear ATG5 induced mitotic
catastrophe, which, however, did not immediately trigger cell
death, as long as autophagy pathways were active. These data
support the view that mitotic catastrophe is not per se a cell death
mechanism6,7.
Treatment of multiple cancer cell lines with etoposide or
cisplatin resulted in increased ATG5 expression. Although the
molecular mechanisms following DNA damage, particularly the
transcriptional regulation of ATG5 gene expression, remain to be
determined, we analysed the functional consequences of increased
ATG5 expression following drug treatment. Using two different
shRNA ATG5 approaches for blocking increased ATG5 expres-
sion, we demonstrated that elevated levels of ATG5 are necessary
for both drug-induced autophagy and mitotic catastrophe. To
show that ATG5 is sufﬁcient for inducing the same effects, we
overexpressed ATG5 in cancer cells. In agreement with earlier
work23, enforced ATG5 expression resulted in increased levels of
autophagy as assessed by LC3-II and p62 immunoblotting.
Increased autophagic ﬂux was additionally demonstrated by
analysing the amount of LC3-II in the presence and absence of a
lysosomal protease inhibitor. Moreover, besides induction of
autophagy, we observed cell enlargement, aberrant nuclei,
multinuclear cells and multipolar mitosis, suggesting that cells
undergo mitotic catastrophe following both DNA-damaging drug
treatment or ectopic ATG5 overexpression. Indeed, ATG5
overexpression itself, similar to etoposide and cisplatin
treatment, resulted in Chk2 activation and inactivation of the
cyclin B1/cdk1 complex, consistent with the induction of a G2
arrest31.
The activation of Chk2 after ATG5 gene transfer suggested that
ATG5 overexpression might have caused DNA damage, which
could have activated the G2 checkpoint and explain the observed
cell cycle arrest. However, immunoblots showed no evidence for
increased phosphorylation of H2AX, ATM or ATR, three
markers of the DNA damage response. Assessing phosphorylated
H2AX by ﬂow cytometry and confocal microscopy, we observed
no or only very subtle DNA damage, which, however, is unlikely
to explain the major mislocalization of survivin and Aurora B
during mitosis. With our approach, quantitative data obtained
with ﬂow cytometry was based solely on DNA amount and failed
to distinguish between G2 phase and M phase cells. On the basis
of microscopic examination of stained cells and counts of 1,000
cells for each time point, the fraction of abnormal nuclei was 14%
Figure 8 | Nuclear ATG5 physically interacts with survivin. (a) Lysates of Jurkat T cells overexpressing ATG5 or treated with etoposide (48-h cultures)
were immunoprecipitated with anti-ATG5 or antisurvivin antibodies. A physical interaction between ATG5 and survivin, absent in untreated or GFP-
expressing control cells, was detected reciprocally. Full-length immunoblots are provided in Supplementary Fig. S12. (b) Jurkat Tcells overexpressing ATG5-
DNES exhibited no ATG5/survivin molecular interaction. (c) The ATG5-K130R mutant did show coprecipitation of survivin with ATG5. (d) Calpain-
mediated, truncated ATG5 (tATG5), that is, the N-terminal part of ATG5, failed to bind survivin. The ATG5-K130R mutant was the control. (e) Confocal
microscopy. MDA-MA-231 cells were etoposide treated or transduced as indicated (48-h cultures) and stained. In untreated cells, survivin and ATG5 were
in the cytosol with no colocalization. ATG5-transduced cells exhibited ATG5/survivin colocalization in the nucleus. ATG5-DNES-transduced cells showed
survivin, but not ATG5, in the nuclei of cycling cells. Numerical analysis was performed and Pearson’s correlation coefﬁcients are indicated in the images.
Scale bar, 10mm. Right: Statistical analysis (analysis of variance) is presented in which the results of ten representative cells within each group were
integrated. Values are means±s.d. (f) The physical interaction between Aurora B and survivin was analysed reciprocally and reduced in cells expressing
high levels of nuclear ATG5. Neither ATG5 nor HSP90 were detectable in the Aurora B-containing immune precipitate, but ATG5 molecularly interacted
with survivin. Results representative of three independent experiments. (g) Confocal microscopy. HeLa cells treated with etoposide or transduced as
indicated (48-h cultures) were stained with centromere-speciﬁc antiserum and anti-Aurora B (top panels) or antisurvivin antibodies (lower panels). In
untreated or ATG5-DNES transduced cells, both Aurora B and survivin were recruited to prometaphase centromeres and located at the central spindle
during anaphase where they no longer colocalized with centromeres. In contrast, etoposide-treated or ATG5-transduced cells recruited much less Aurora B
to prometaphase centromeres. Such recruitment, however, was observed during anaphase. Compared with cells in normal mitosis, survivin, although
reduced, was recruited to centromeres in prometaphase, but, similar to Aurora B, remained attached to centromeres during anaphase. Such mislocation of
Aurora B and survivin was associated with severe chromosome alignment and segregation defects. Colocalization images were prepared using Imaris
software. Numerical analysis was performed and correlation coefﬁcients are indicated. Scale bar, 2 mm. (h) Confocal microscopy. Sections of lung
(non-small-cell lung cancer) and oesophageal carcinoma stained for ATG5 and survivin expression. In untreated patients, ATG5 expression in cancer cells
was slight and mainly cytosolic. Following radio- and/or chemotherapy, ATG5 was preferentially expressed in the nucleus and colocalized with survivin.
Overlay images present the average Pearson’s correlation coefﬁcient as calculated with Imaris. Results are representative of three independent
experiments. Scale bar, 10mm.
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at 24 h after transfection, 45% at 48 h and 57% at 72 h. The
fraction of cells in mitosis was relatively constant at 2.8–3.6%.
These values correspond fairly well with the G2 phase plus
M-phase fraction found with ﬂow cytometry.
We also studied the possible role of p53, which is required for
induction of cell death following DNA damage32. Using p53-
inducible Saos-2 cells, we obtained no evidence for a role of p53
in ATG5-mediated mitotic catastrophe (Supplementary Fig. S7), a
ﬁnding that is in agreement with another report33. On the other
hand, it has been suggested that the ﬁnal fate of cells suffering
mitotic catastrophe may depend on the status of p53 (ref. 34).
Thus, we must speculate that some activity of ATG5 leads to
crosstalk with the DNA damage response pathway.
The fact that autophagy protects cells from genotoxic stress
and maintains genome integrity has already been established35.
Autophagy, however, is unlikely to be itself responsible for the G2
arrest and mitotic catastrophe for the following reasons. First,
autophagy induced by the overexpression of Beclin 1 or starvation
did not lead to mitotic catastrophe. Second, 3-MA, an inhibitor of
autophagy, did not block ATG5-mediated effects on cell cycle or
mitotic catastrophe. Third, a mutant ATG5, unable to conjugate
with ATG12 and incompetent to initiate autophagy, still induced
G2 arrest and mitotic catastrophe. Together with earlier
work14,23, these data suggest that ATG5 exerts alternative
functions beyond and independent of autophagy.
The nuclear localization of ATG5 was a surprising ﬁnding,
observed not only in cell lines but also in the lung and
oesophageal carcinoma tissues. But how can ATG5 translocate
to the nucleus? We identiﬁed a conserved putative NES in ATG5
without, however, any canonical NLS36. This lack is not
infrequent with proteins entering the nucleus37. HIV-1 vpr
exhibits no canonical NLS, but carries an arginine-rich region,
which overlaps with and inﬂuences recognition of the leucine-
rich NES. This region is both a functional NLS and a NES, having
a role in nuclear shuttling of protein and viral nucleocapsid at the
time of initial infection37,38.
We prepared mutants of the putative NES of ATG5, replacing
three of the conserved leucines with alanines (ATG5-DNES).
Following mutagenesis of conserved leucines in this sequence, we
observed, not as expected, an increased accumulation of ATG5 in
the nucleus owing to a failure of export, but rather, much like the
pattern with vpr, the absence of ATG5 in the nucleus. Most
interestingly, ATG5-DNES also fails to cause G2 arrest or mitotic
catastrophe. Inhibition of the CRM1-dependent nuclear export
following leptomycin B treatment of cells overexpressing wild-
type ATG5 does lead to nuclear accumulation.
Survivin protects cells from apoptosis both in vitro and in vivo
by inhibiting the mitochondrion/caspase-9-activated ‘intrinsic’
pathway and is associated with an X-linked inhibitor of apoptosis
protein39,40. Survivin also regulates cell division and participates
in forming the chromosome passenger complex responsible for
chromosome segregation21,24. Hence, survivin is expressed in the
G2 phase of cell cycle41. It has also been shown that survivin is
strongly expressed in most human cancers42. We demonstrate
here that certain DNA-damaging drugs upregulate both ATG5
and survivin expression, which, subsequently, colocalize in the
nucleus. Physical interaction between ATG5 and survivin was
demonstrated by both immunoprecipitation experiments and
confocal microscopy. Importantly, we also show here
upregulation and colocalization of ATG5 and survivin, as well
as evidence for reduced survivin–Aurora B molecular interactions
under in vivo conditions using patient-derived cancer tissues.
ATG5-DNES, unable to enter the nucleus, did not associate
with survivin and did not induce a G2 arrest or abnormal mitosis.
Thus, the association of ATG5 and survivin is consistent with the
observed mitotic defects in metaphase, because survivin
contributes to chromatin-associated spindle formation21.
However, as shown in this report it is likely that this molecular
interaction changes the composition of the chromosomal
passenger complex, as the interaction between Aurora B and
survivin was seen to be reduced. Moreover, we obtained evidence
that both Aurora B and survivin were displaced in prometaphases
and anaphases in cells undergoing abnormal mitosis after
etoposide treatment or enforced ATG5 expression. These
abnormalities were associated with a severe disturbance in
chromosome alignment and segregation. In agreement with
these ﬁndings, Aurora B mislocation had previously been
reported to result in loss of chromosome alignment and
disruption of cytokinesis in the absence of cell death28. Mitotic
catastrophe has previously been observed in cells treated with
small interfering RNA survivin43. Therefore, it is likely that
nuclear ATG5 acts as a functional survivin antagonist leading to
Aurora B mislocation during mitosis. These abnormalities,
however, are also associated with the displacement of survivin
itself, particularly during anaphase. Regardless of the exact
molecular consequences of the ATG5/survivin molecular
interactions, our data suggest that ATG5 interferes with the
roles of survivin and Aurora B in chromosome alignment and
segregation during mitosis.
Thus, ATG5, similar to survivin, exhibits different roles in the
cytosol and nucleus. The two different roles of ATG5 are of
obvious medical importance in connection with anticancer
therapy. Moreover, our data explain, at least partially, why
autophagy can have tumour-promoting activities4. The fraction
of cells that survive mitotic catastrophe is aneuploid, genetically
highly diverse and, therefore, potentially very dangerous6,7.
Inhibition of autophagy seems to be a reasonable therapeutic
strategy to induce cell death under conditions of mitotic
catastrophe.
Methods
Reagents. Rapamycin, hydroxyurea, nocodazole, staurosporine, taxol, PI, 3-MA,
chloroquine and leptomycin B were purchased from Sigma-Aldrich (Buchs,
Switzerland). Etoposide was from Bristol-Myers Squibb AG (Baar, Switzerland)
and cisplatin from Nycomed Pharma AG (Du¨bendorf, Switzerland). If not other-
wise indicated, etoposide was used at 0.25 mM and cisplatin at 3 mM. The caspase
inhibitor zVAD-ﬂuoromethylketone was obtained from BD Biosciences (Erem-
bodegem, Belgium). DAPI (40 ,6-diamidino-2-phenylindole) was from Invitrogen
(Paisley, UK).
Cells. MDA-MA-231 and HeLa cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). NB4 cells were from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen, GmbH (DSMZ,
Braunschweig, Germany). Jurkat T cells (J16 clone) were the gift of Dr M. Peter
(German Cancer Research Center, Heidelberg, Germany). HKF1-(HeLa Kyoto with
FRT-site) H2B–mCherry–a-tubulin–EGFP cells were provided by Dr D.W. Gerlich
(Institute of Biochemistry, ETH Zurich, Zurich, Switzerland)9. HeLa cells
expressing GFP-LC3 were the gift of Dr T. Yoshimori, Osaka University, Osaka,
Japan)44. Jurkat T and NB4 cells were grown in RPMI 1640 (Life Technologies)
with 10% heat-inactivated FCS. HeLa and MDA-MA-231 cells were grown in
DMEM supplemented with 5% heat-inactivated FCS.
Tumour tissues. Specimens were parafﬁn sections from surgical material of six
oesophageal carcinoma and six non-small-cell lung cancer patients obtained from
the archive of the histology laboratory of the Institute of Pathology, University of
Bern. The study was approved by the internal review board of the University
Hospital Bern. Patients were either untreated or had received several cycles of
standard neoadjuvant chemotherapy (lung cancer patients: cisplatin and
docetaxel45) or combined radio- and chemotherapy (oesophagus patients: cisplatin
and 5-ﬂuorouracil46).
Site-directed mutagenesis. The ATG5-DNES mutant lacking the NES was
constructed essentially as described for Beclin 1 (ref. 19). Amino acid mutations on
L39A, L45A and L47A were generated using QuickChange Site-Directed
Mutagenesis Kit (Stratagene Europe, Amsterdam, The Netherlands) using the
following primer sequences: forward, 50-TAC TAT TTG CTT GCA CCA AGA
GTA AGT TAT GCT ACG GCA GTA ACT GAC AAA-30 and reverse, 50-TTT
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GTC AGT TAC TGC CGT AGC ATA ACT TAC TGG TGC AAG CAA ATA
GTA-30 . The ATG5-K130R mutant, unable to conjugate with ATG12, was
generated as previously described14. The mutated ATG5 sequences were conﬁrmed
by sequence analysis. The constructs were subcloned into the pWPT vector.
Lentiviral gene transfer and gene silencing. Human ATG5 (Gene ID: 9474,
NM_004849), ATG5-DNES, ATG5-K130R, calpain-mediated truncated ATG5
(ref. 4) and GFP were subcloned into the HIV-derived vector pWPT, containing a
cytomegalovirus promoter47. Two types of shRNA ATG5 were used: ATG5-1
shRNA was subcloned in pMSCV-Puro-miR30 (ref. 48), which was the gift of Dr
M. Narita (Cambridge Research Institute, Cambridge, UK), as well as ATG5-2
shRNA, which was in pLKO.1 and obtained from Sigma-Aldrich. Human Beclin 1
(Gene ID: 8678, NM_003766) was subcloned in a CAD vector containing GFP49,
which was obtained from Dr M. Tschan (Department of Clinical Research,
University of Bern, Bern, Switzerland). Recombinant virus constructs were
produced by calcium phosphate transfection together with the envelope vector
PMD2.G and the packaging vectors psPAX2 for lentivirus (all provided by Dr
D. Trono, University of Geneva, Switzerland) into 293T cells. For virus stocks, the
supernatant was collected 24, 48 and 72 h after transfection and cleared. Virus was
immediately concentrated at 4 C in a Beckman Coulter ultracentrifuge (Palo Alto,
CA, USA) with the SW41-Ti rotor (RCF: 55,000 g for 90min). Pellets were re-
suspended in RPMI 1640 medium with 10% FCS in 1/10th the volume of the
original culture supernatant. Concentrated virus was used at a multiplicity of
infection of 25 as described50. The expression of transduced genes was controlled
by immunoblotting. The efﬁcacy of gene transfer was controlled by counting GFP-
positive cells following pWPT-GFP transduction and was between 90 and 100%.
Gel electrophoresis and immunoblotting. Cells (0.5–1.0 106) were washed with
Dulbecco’s PBS (DPBS), lysed with lysate buffer (50mM Tris, pH 7.4, 150mM
NaCl, 10% glycerol, 1% Triton-X100, 2mM EDTA, 10mM Na4P2O7, 50mM NaF,
200mM Na3VO4) or with 2 SDS loading buffer, and cell lysates passed 10–15
times through a 26-gauge needle. Equal amounts of protein (30–50 mg per lane) of
the cell lysates were loaded on NuPAGE gels (Invitrogen). Gels were electroblotted
onto polyvinylidene diﬂuoride membranes (Immobilion-P; Millipore). The blots
were incubated with primary antibodies at 4 C overnight in transfer buffer solu-
tion with 0.1% Tween-20 and 5% non-fat dry milk and developed with the
ECL-technique (ECL-Kit, Amersham). Primary antibodies were purchased as
follows: monoclonal antihuman ATG5 and anti-LC3 antibodies were from
NanoTools (Taningen, Germany). Polyclonal rabbit, afﬁnity-puriﬁed antiphospho-
Chk2 (Thr68), antiphospho-cdk1 (Tyr15), anticaspase-3 and anti-Beclin 1, as well
as monoclonal mouse anticyclin B1, rabbit antisurvivin, rabbit anti-Aurora B,
rabbit anti-HSP-90 and rabbit antiphospho-ATR (Ser428) antibodies were
obtained from Cell Signaling Technology (Danvers, MA, USA). Monoclonal
antiphospho-H2AX (Ser139) and antiphospho-ATM (Ser1981) antibodies were
from Upstate Cell Signaling Solutions (Lake Placid, NY, USA). Rabbit anti-p62
antibody was from Sigma-Aldrich and anti-ATG12 antibody from R&D Systems
(Minneapolis, MN, USA). Monoclonal mouse antisurvivin and anti-cdk1, as well as
polyclonal goat anti-lamin B and rabbit antiborealin antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). All primary antibodies were used at
1:500 or 1:1,000 dilutions. Monoclonal anti-GAPDH antibody was from Chemicon
International, Inc. (Temecula, MA, USA) and used at 1:5,000.
Subcellular fractionation. Jurkat T cells (10–30 106) were treated and genetically
modiﬁed as indicated, cultured as indicated, then washed with cold PBS, resus-
pended in hypotonic lysis buffer (10mM Hepes, pH 8, 5mM KCl, 2mM MgCl2,
2mM DDT) and Dounce homogenized (10–15 strokes) on ice. To separate cyto-
plasmic (supernatant) and nuclear (pellet) fractions, the homogenate was cen-
trifuged at 1,000 g for 5min at 4 C. The fractions were lysed by addition of 2 SDS
loading buffer, equal amounts of proteins were loaded on 12% NuPAGE gels, and
subsequently transferred onto polyvinylidene diﬂuoride membranes as described
above. Caspase-3 and lamin B were used as markers to control the fractionation.
Coimmunoprecipitation. Jurkat T cells (1 107) were lysed in total lysate buffer
(50mM Tris, pH 7.4, 150mM NaCl, 40mM b-glycerol phosphate, 10mM NaF,
0.5% (vol/vol) IGEPAL, 0.1% deoxycholate, 30 mgml 1 RNase, 80Uml 1
micrococcal nuclease (Sigma-Aldrich), 10 mm prefabloc, protease inhibitor cocktail
tablets (Roche Diagnostics), 100mM ATP, 100mMMgCl2, 100 nM okadaic acid and
0.3mM Na-vanadate). Lysates were passed 20–30 times through a 26-gauge needle,
centrifuged and precleared by centrifugation after incubation at 4 C with 10ml of
prewashed 50% Protein A/Protein G-agarose beads (Santa Cruz) for 1 h. Primary
antibodies used were: rabbit polyclonal anti-ATG5 (2 mg), rabbit antisurvivin
(2mg), rabbit anti-Aurora B (2mg) (all Cell Signaling Technology), or rabbit IgG
control (2 mg) (Dako, Baar, Switzerland). Overnight incubation with primary
antibodies was followed by a 2-h incubation at 4 C with 30 ml of pre-washed 50%
Protein A/Protein G-agarose beads. Immunocomplexes were washed four times
with lysis buffer, denatured, loaded on a 12% NuPAGE gel and processed by
immunoblotting as described above.
Confocal laser-scanning microscopy. Cells were grown on washed coverslips,
ﬁxed and permeabilized. Indirect immunostainings were performed at 4 C over-
night using the following primary antibodies: monoclonal anti-ATG5 (1/100;
Nanotools), rabbit antisurvivin antibody (1/500; Cell Signaling Technology), rabbit
anti-aurora B antibody (1/100; Cell Signaling Technology), centromere antiserum
(1/800; Europa Bioproducts Ltd, Cambridge, UK) and monoclonal antiphospho-
H2AX (1/1,000). Mouse and rabbit control antibodies were used at the same
concentrations in each experiment. Incubation with appropriate Alexa Fluor 488
goat antimouse IgG and Alexa Fluor 532 goat antirabbit IgG (both Molecular
Probes and Invitrogen), as well as APC donkey anti-mouse IgG (Jackson Immu-
noResearch, West Baltimore Pike, PA, USA) was performed in the dark at room
temperature for 1 h. The coverslips were mounted on slides using Prolong Gold
containing DAPI (Invitrogen). The slides were analysed by confocal laser-scanning
microscopy (LSM 5 Exciter microscope, Carl Zeiss, Jena, Germany). Expression of
ATG5, survivin and Aurora B was also analysed in parafﬁn-embedded tissue
specimens derived from surgical material of cancer patients by immuno-
ﬂuorescence51. For colocalization studies, unprocessed data sets were analysed
using the Imaris software (Bitplane AG, Zurich, Switzerland), considering each
single layer of a stack separately. Quantitative data for colocalization events were
determined by the statistics modules in the colocalization and Voxelshop software
of the Imaris package. Intensities were given as sum of all colocalizing voxels in a
data set, and a computer image was generated. For quantitative analysis of
colocalization, the Pearson’s correlation coefﬁcient was calculated52.
Time-lapse microscopy. HeLa H2B–mCherry–a-tubulin–mEGFP cells were
seeded on glass-bottomed tissue culture dishes (MatTek Corporation, Ashland,
MA, USA) and transduced with lentiviral particles containing human full-length
ATG5, human Beclin 1 or GFP. Time-lapse microscopy data were acquired using
an Axio observer microscope (Carl Zeiss) equipped with a camera (Digital Pixel
Imaging) and a full-enclosure environmental chamber heated to 37 C with 5%
CO2 and humidiﬁer. Frames were recorded every 5min for a total of 72 h
(Supplementary Movies 1–4). Fluorescence was visualized through an LSM 5
Exciter microscope (AOTF attenuation of 3%, laser lines 488 nM and 543 nM.
Photomultiplier tube voltage was 802V, ampliﬁer offset  0.223) and acquisition
was performed using a Plan-Apochromat objective ( 63, numerical aperture 1.4,
oil immersion) and a 270-mm confocal pinhole aperture. Time periods between
nuclear envelope breakdown and anaphase were determined as previously
reported53.
Flow cytometry. For cell cycle analysis, cells were treated and genetically modiﬁed
as indicated, washed with DPBS containing 2% FCS, ﬁxed with 70% ethanol at
 20 C for 1 h, pelleted, resuspended in DPBS and permeabilized with 0.125%
Triton X-100. RNase (0.2mgml 1) was added and cells were stained with
40 mgml 1 PI. Viability was assessed by exclusion of 1 mM ethidium bro-
mide23,54,55. The expression of phosphorylated H2AX was measured following
staining, which is described above (confocal microscopy). Cells were analysed by
ﬂow cytometry (FACS Calibur, BD Biosciences), and data processed by FlowJo
software (Tree Star, Inc., Ashland, OR, USA).
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